Abstract 917P
Background
Patients with oral cavity squamous cell carcinoma (OCSCC) are at high risk of death within 5 years of treatment. Previous works have demonstrated that spatial arrangement of tumor-infiltrating lymphocytes (TILs) and surrounding nuclei (e.g, cancer nuclei, macrophages, fibroblasts) is prognostic of overall survival (OS) in different types of cancer, including oropharyngeal and laryngeal. In this work, we evaluated the prognostic ability of a computerized strategy that characterizes the spatial arrangement of TILs & non-TILs on digitized H&E-stained slides of patients with OCSCC.
Methods
Whole slide images (WSIs) from a cohort of 283 patients with OCSCC were retrospectively collected from the Cancer Genome Atlas (TCGA, D1). Additionally, WSIs from 136 patients with OCSCC were obtained from Vanderbilt University Medical Center (VUMC, D2). D1 was used to train a prognostic model while D2 was used for independent validation. Computer algorithms automatically identified 2 types of nuclei (TILs & non-TILs) and built clusters for each nucleus type based on proximity. Metrics related to density, intersection, and neighborhood were computed from these clusters. A proportional hazard Cox regression model, regularized via the least absolute shrinkage and selection operator, was trained to predict risk of death. The percentile 66 risk score on D1 was used as a threshold for stratifying patients on D2 as either low or high risk. Survival analysis was then used to evaluate the association with OS.
Results
Patients in D2 defined as “low risk” (57%) based on spatial arrangement of TILs has significantly better OS than those identified as “high risk” (43%) with hazard ratio=3.84 (95% confidence interval: 1.39-10.6, p<0.01). Multivariable survival analysis showed that this model was prognostic independent of age and overall, T, and N stages with HR=2.88 (95% CI: 1.10-7.56, p=0.03).
Conclusions
A computerized image analysis model based on measurements of spatial arrangement of TILs & non-TILs was found to be prognostic in patients with OCSCC. With more modeling and development, this model may provide a risk classifier for use in routine clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Madabhushi.
Funding
US National Institutes of Health, US Department of Defense.
Disclosure
A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Amanda Psyrri
Session: Poster session 03
941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Saira Khalique
Session: Poster session 03
942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)
Presenter: Laiping Zhong
Session: Poster session 03
Resources:
Abstract
945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Presenter: Jean-Pascal Machiels
Session: Poster session 03
1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safety
Presenter: Ruofan Huang
Session: Poster session 03
1003P - A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
Presenter: Mathilde Beaufils
Session: Poster session 03